Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Timonacic, also known as thioproline, is a thiazolidine derivative that serves as a hepatoprotective agent and a metabolic scavenger of formaldehyde. Chemically, it is the condensation product of L-cysteine and formaldehyde (1,3-thiazolidine-4-carboxylic acid). It is primarily utilized in the treatment of various liver conditions, including nonalcoholic fatty liver disease (NAFLD), chronic hepatitis, and toxic liver injury, where it acts as a donor of sulfhydryl groups to support detoxification and protect hepatocytes from oxidative damage. Beyond its established role in hepatology, timonacic has been investigated for its ability to modulate the inflammatory microenvironment and enhance the translational efficiency of mRNA when incorporated into lipid nanoparticle (LNP) delivery systems for applications such as skin rejuvenation and the de novo synthesis of elastin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on timonacic.